NASDAQ:TNGX
Tango Therapeutics, Inc.
Tango Therapeutics, Inc.'s revenue grew 48.3% in fiscal 2025 to $62.4M while operating margin rose to −178.4%. Free cash flow was −$139.9M, −224.3% of revenue, and the diluted share count rose 6.4%.Summary generated from Tango Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 5, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$62.4M
Revenue growth+48.3%
Revenue, 5-yr CAGR+52.1%
Gross marginn/a
Operating margin−178.4%
Net margin−162.9%
ROICn/a
Return on equity−37.2%
Debt / equityn/a
Free cash flow−$139.9M
FCF margin−224.3%
Share count change+6.4%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 37 | 25 | 37 | 42 | 62 |
| Operating income | −58 | −111 | −114 | −146 | −111 |
| Net income | −58 | −108 | −102 | −130 | −102 |
| Free cash flow | −61 | −117 | −120 | −132 | −140 |
Recent filings
- 4Insider transaction report
Oct 5, 2026 - 4Insider transaction report
Sep 24, 2026 - 8-KOther events
Aug 11, 2026 - 8-KResults of operations and financial condition
Aug 11, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 11, 2026 - 8-K/AAmended director or officer change
Aug 7, 2026 - 8-KDirector or officer change
Aug 6, 2026 - 8-KDirector or officer change
Jun 23, 2026